Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2017
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Luitpold Pharmaceuticals
- 24 May 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 Planned End Date changed from 1 Jul 2018 to 1 Mar 2020.
- 09 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2019.